- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8810
| Related Targets | EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 |
|---|---|
| Other Serine/threonin kinase Products | WNK463 SRPIN340 Benzamidine HCl GCN2iB DCLK1-IN-1 WNK-IN-11 14-3-3 η Antibody [G4H24] MKI-1 STK16-IN-1 2OH-BNPP1 |
|
In vitro |
DMSO
: 25 mg/mL
(49.26 mM)
Ethanol : 13 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 507.51 | Formula | C27H24F3N5O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1818389-84-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CN(CCN1CC2=CC=CC=N2)C3=C(C=C(C=C3)C(F)(F)F)NC(=O)C4=CC=C(O4)C5=CC=NC=C5 | ||
| Targets/IC50/Ki |
SRPK1
(Cell-free assay) 5.9 nM
|
|---|---|
| In vitro |
Kinase assays showed that SPHINX31 is a type 1 kinase inhibitor (ATP competitive). This compound treatment results in inhibition of SRSF1 phosphorylation at 300 nM in PC3 prostate cancer cells. Metabolic stability in mouse liver microsomes shows that this chemical had medium clearance with a T1/2 of 95.79 min. Inhibition of SRPK1 using this inhibitor leads to cell cycle arrest and leukemic cell differentiation. |
| In vivo |
SPHINX31 could penetrate into the eye. This compound exerts a dose dependent inhibition of choroidal neovascularisation in mouse model. It inhibits blood vessel growth and macrophage infiltration. This chemical treatment prolongs survival of immunocompromised mice transplanted with MLL-rearranged AML cells. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.